Journal: Cancers

Article Title: Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

doi: 10.3390/cancers16173104

Figure Lengend Snippet: SSTR expression and in vitro effects of lanreotide on healthy human T cell function and survival. ( A ) Expression of SSTR receptors 1–5 on Tc ( left graph), Th ( middle graph), and Treg ( right graph) cell populations showing SSTR2 to be the most abundantly expressed SSTR in all T cell populations studied. ( B ) Effects of in vitro lanreotide exposure on T cell function and survival. Function measured as IFNg ( left graph) and IL-2 ( middle graph) production, and survival measured by apoptosis assay ( right graph). ( C ) Effects of in vitro lanreotide exposure on transcription factor signaling measured by activity of NFAT ( left graph), NFkB ( middle graph) or ERK1/2 ( right graph). N = 10 for all experiments.

Article Snippet: Healthy donor peripheral blood was pre-treated with lanreotide (Selleck chemicals, Houston, TX, USA) at concentrations up to 10 mcM overnight at 37 °C/5% CO 2 before incubation with or without Phorbol-12-myristate-13-acetate (PMA)/Ionomycin/Brefeldin A mix for 4 h at 37 °C/5% CO 2 .

Techniques: Expressing, In Vitro, Cell Function Assay, Apoptosis Assay, Activity Assay

Journal: Cancers

Article Title: Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

doi: 10.3390/cancers16173104

Figure Lengend Snippet: In vitro effects of lanreotide exposure on the PMA/Ion- or anti-CD3/CD28-activation of NFAT1, NF-κB(p65) or ERK1/2. Mean similarity score (SS) values were obtained from 10 healthy donors with the associated standard errors (SE).

Article Snippet: Healthy donor peripheral blood was pre-treated with lanreotide (Selleck chemicals, Houston, TX, USA) at concentrations up to 10 mcM overnight at 37 °C/5% CO 2 before incubation with or without Phorbol-12-myristate-13-acetate (PMA)/Ionomycin/Brefeldin A mix for 4 h at 37 °C/5% CO 2 .

Techniques: In Vitro

Journal: Cancers

Article Title: Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

doi: 10.3390/cancers16173104

Figure Lengend Snippet: The patient-, treatment-, and interaction-analysis of lanreotide exposure in vivo in 3 T cell subsets (Tc, Th, Treg).

Article Snippet: Healthy donor peripheral blood was pre-treated with lanreotide (Selleck chemicals, Houston, TX, USA) at concentrations up to 10 mcM overnight at 37 °C/5% CO 2 before incubation with or without Phorbol-12-myristate-13-acetate (PMA)/Ionomycin/Brefeldin A mix for 4 h at 37 °C/5% CO 2 .

Techniques: In Vivo

Journal: Cancers

Article Title: Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

doi: 10.3390/cancers16173104

Figure Lengend Snippet: Proteomic and transcriptional analysis of in vivo lanreotide treatment in T cell subsets from NET patients. Paired samples obtained before and after treatment were analyzed for each patient. Volcano plots show a linear mixed model (LMM) analysis of Tc ( left graphs), Th ( middle graphs), and Treg ( right graphs) cell populations fitted to test three different effects. The ‘Patient Effect’ ( upper graphs) estimated if any gene was significantly different between Responder and Non-responder pre-treatment, where non-responders served as reference. The ‘Treatment effect’ ( middle graphs) estimated if any genes were significantly changed between pre-treatment and post-treatment (regardless of response). For this analysis, the pre-treatment samples served as a reference. The ‘Interaction Effect’ estimated whether any genes were significantly changed before and after treatment in responders versus non-responders, where non-responders served as reference (lower graphs). Plots show the statistical significance ( p value) versus the magnitude of change (fold change) for each of the 9 categories.

Article Snippet: Healthy donor peripheral blood was pre-treated with lanreotide (Selleck chemicals, Houston, TX, USA) at concentrations up to 10 mcM overnight at 37 °C/5% CO 2 before incubation with or without Phorbol-12-myristate-13-acetate (PMA)/Ionomycin/Brefeldin A mix for 4 h at 37 °C/5% CO 2 .

Techniques: In Vivo

Journal: Cancers

Article Title: Immune Cell Molecular Pharmacodynamics of Lanreotide in Relation to Treatment Response in Patients with Gastroenteropancreatic Neuroendocrine Tumors

doi: 10.3390/cancers16173104

Figure Lengend Snippet: Expression of genes of note from transcriptional analysis of in vivo lanreotide treatment in T cell subsets from NET patients. ( A ) Expression of TXNIP in non-responders (red bar) and responders (teal bar) in Tc ( left graph), Th ( middle graph), and Treg cells ( right graph). ( B ) Most significantly altered genes between non-responders and responders pre-treatment shown for Th ( left graph), Treg ( middle graph), and Tc cells ( right graph). ( C ) Expression of TXNIP in Tc cells pre- and post-treatment in non-responders and responders indicates upregulation with lanreotide treatment in responders only. ( D ) Interaction effect, i.e., significant change in gene expression between non-responders and responders following treatment shown for CCRL2 in TC cells ( right graph).

Article Snippet: Healthy donor peripheral blood was pre-treated with lanreotide (Selleck chemicals, Houston, TX, USA) at concentrations up to 10 mcM overnight at 37 °C/5% CO 2 before incubation with or without Phorbol-12-myristate-13-acetate (PMA)/Ionomycin/Brefeldin A mix for 4 h at 37 °C/5% CO 2 .

Techniques: Expressing, In Vivo, Gene Expression

Journal: Scientific Reports

Article Title: Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT

doi: 10.1038/s41598-021-99048-8

Figure Lengend Snippet: Selected study population.

Article Snippet: The following previous therapies were also considered as possible predictive factors of CTCAE onset: splenectomy, everolimus, alkylating chemotherapy and MetNET protocol (Lanreotide and Metformin) .

Techniques:

Journal: Scientific Reports

Article Title: Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT

doi: 10.1038/s41598-021-99048-8

Figure Lengend Snippet: P-values of Chi square/Fisher tests to evaluate the association between CTCAE and the independent variables; p-value of Wilcoxon’s test for variable Age.

Article Snippet: The following previous therapies were also considered as possible predictive factors of CTCAE onset: splenectomy, everolimus, alkylating chemotherapy and MetNET protocol (Lanreotide and Metformin) .

Techniques:

Journal: Surgical oncology clinics of North America

Article Title: MEDICAL MANAGEMENT OF GEPNETS

doi: 10.1016/j.soc.2019.11.004

Figure Lengend Snippet: Somatostatin analog trials

Article Snippet: METNET-2 Pilot one arm open label prospective study , Advanced GI or lung well differentiated NETs , Lanreotide and Metformin 2550mg daily , 20 , NCT02823691.

Techniques: Control, Titration

Journal: Surgical oncology clinics of North America

Article Title: MEDICAL MANAGEMENT OF GEPNETS

doi: 10.1016/j.soc.2019.11.004

Figure Lengend Snippet: Somatostatin analog ongoing or recently completed clinical trials

Article Snippet: METNET-2 Pilot one arm open label prospective study , Advanced GI or lung well differentiated NETs , Lanreotide and Metformin 2550mg daily , 20 , NCT02823691.

Techniques:

Journal: Surgical oncology clinics of North America

Article Title: MEDICAL MANAGEMENT OF GEPNETS

doi: 10.1016/j.soc.2019.11.004

Figure Lengend Snippet: Randomized clinical trials with interferons

Article Snippet: METNET-2 Pilot one arm open label prospective study , Advanced GI or lung well differentiated NETs , Lanreotide and Metformin 2550mg daily , 20 , NCT02823691.

Techniques: Clinical Proteomics